TDC
PCRX icon

Thompson Davis & Co’s Pacira BioSciences PCRX Stock Holding History

Thompson Davis & Co’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-251
Closed -$9K – 961
2017
Q3 		$9K Buy
+251
New +$10.1K 0.02% 716

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Thompson Davis & Co's PCRX Position: Q4 2017 in Review

Thompson Davis & Co sold out of Pacira BioSciences (PCRX) in Q4 2017, closing a stake of 251 shares — an estimated $9K sold.

Thompson Davis & Co first reported a position in PCRX in Q3 2017 and held it in 1 quarter. The position peaked at $9K in Q3 2017. 185 funds tracked by Wall St. Rank hold PCRX as of Q4 2017.

  • Thompson Davis & Co reported no remaining Pacira BioSciences position as of Q4 2017 after selling out during the quarter.
  • Thompson Davis & Co sold 251 Pacira BioSciences shares in Q4 2017, an estimated $9K.
  • Thompson Davis & Co first reported a position in Pacira BioSciences in Q3 2017 and held it in 1 quarter.
  • Thompson Davis & Co's Pacira BioSciences position peaked at $9K in Q3 2017.
  • 185 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.